Good Signal Weekly Pulse — Edition 7 (November 9, 2025)
Published · Researched 2026-09-22
Week of November 3, 2025
The week in one paragraph
The Bronx Pizza Man turned a moment of shame into a standing policy of mercy. In August 2026, Daniel Romano — owner of D'Romano's Pizza on East Tremont Avenue in Throggs Neck, back in the business at 50 after decades in pizza — spotted an elderly woman pulling a half-eaten slice from his restaurant's trash can. He brought her inside, heated her a fresh slice, and comforted her. Then he posted a handwritten sign in his window inviting anyone eating from his garbage to come inside, say they're hungry, and receive a free slice and fresh water — forever. After Fox 5, NBC New York, the Bronx Times, and PMQ covered it in late August, strangers across the country began calling the shop to prepay slices for people in need, customers donated whole pies, and a neighboring salon offered free back-to-school haircuts. The story circulated via @goodnews_movement on Instagram, viral YouTube Shorts retellings, and an iHeart "Happy News" segment. Still watching: the incident itself is only dated "August 2026" in the sources, and Romano's late mother's first name appears as both Carmella (Fox 5) and Camila (a Shorts description) — unresolved.
Rising
Gene medicine's one-shot era. In a Phase 2 trial of 27 adults with hereditary angioedema — unpredictable, potentially life-threatening swelling attacks — one 50 mg infusion of the CRISPR therapy NTLA-2002 cut monthly attacks 77–81%, with 8 of 11 patients in the key cohort completely attack-free and no treatment-attributed serious adverse events. Biotech and investor accounts circulated it on Threads, including word of an FDA Priority Review milestone for the therapy under its commercial name, nexigebart. Still watching: Phase 3 is still required, the therapy is investigational, and the dossier flags the social layer as thin at research time.
A weekly injection against kidney failure. In FLOW — 3,533 adults with type 2 diabetes and chronic kidney disease — weekly semaglutide cut major kidney events and kidney/cardiovascular death 24%, major adverse cardiovascular events 18%, and all-cause mortality 20% versus placebo (NEJM, May 2024). The trial was stopped early in October 2023 when efficacy was clear — the first GLP-1 trial built around a hard kidney-outcome endpoint. NEJM itself highlighted it on Threads as a Notable Article of 2024. Still watching: the dossier flags the social layer as thin at research time.
Veterans getting the welcome they earned. Knoxville gave returning HonorAir veterans a large community welcome home — documented across YouTube, Vimeo, and TikTok, and memorialized in a first-person veteran letter in Knox News (April 28, 2026). Still watching: sources disagree on the headcount (the Knox News letter says 138; a TikTok says 136; a Vimeo caption says 135+), and the flight date wasn't captured.
Falling
The life sentence of hereditary angioedema. Patients live braced for the next attack, managing a disease forever. A one-time infusion that left most treated patients attack-free points at a different future — investigational, but pointed.
Hunger going unseen. One Bronx corner now has a standing open door, and strangers three time zones away are paying for the slices.
Quiet signals
- Hero the fire-truck kitten: found aboard a Coral Springs fire truck during the department's 9/11 remembrance, adopted by Carolyn McGuire, and reported vet-checked, healthy, and thriving on September 18, 2026. Completed adoption — but exact adoption date and the kitten's age are unknown. Early days, worth a check-in.
- Knoxville's missing details: the flight date and HonorAir chapter specifics weren't captured. The welcome is verified; the logistics are thin.
Scoreboard
N/A — editions written out of sequence; no prior calls to grade.
One line to close
A pizza sign that never expires, a CRISPR dose that might never need repeating, and a hometown that showed up for its veterans.